These evaluations may lead to primary or secondary diagnoses of mild cognitive impairment such as Alzheimer’s or Parkinson’s Disease, the latter of which would benefit from dopamine agonists and cholinesterase inhibitors [44]. The gene discussed is BCHE; the disease is Cognitive impairment.